HKD20.65
12.87%
Hong Kong, Apr 07, 10:09 am CET
ISIN
KYG549581067
Symbol
3692
Index
Sector
Industry

Hansoh Pharmaceutical Group Company Target price 2025 - Analyst rating & recommendation

Hansoh Pharmaceutical Group Company Classifications & Recommendation:

Buy
96%
Hold
4%

Hansoh Pharmaceutical Group Company Price Target

Target Price HKD25.76
Price HKD23.70
Potential
Number of Estimates 23
23 Analysts have issued a price target Hansoh Pharmaceutical Group Company 2026 . The average Hansoh Pharmaceutical Group Company target price is HKD25.76. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 24 analysts: 23 Analysts recommend Hansoh Pharmaceutical Group Company to buy, 1 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Hansoh Pharmaceutical Group Company stock has an average upside potential 2026 of . Most analysts recommend the Hansoh Pharmaceutical Group Company stock at Purchase.

Sales and Margin forecast 2025, 2026 to 2029

Create a premium account to unlock analyst estimates. Learn more

Dec '24 2025
Estimates
Revenue Billion HKD 13.29 14.43
19.07% 8.52%
EBITDA Margin 35.51% 36.69%
16.59% 3.33%
Net Margin 35.72% 32.21%
10.15% 9.83%

23 Analysts have issued a sales forecast Hansoh Pharmaceutical Group Company 2025 . The average Hansoh Pharmaceutical Group Company sales estimate is

HKD14.4b
Unlock
. This is
8.52% higher
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
HKD15.6b 17.11%
Unlock
, the lowest is
HKD13.6b 2.25%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2024 HKD13.3b 19.07%
2025
HKD14.4b 8.52%
Unlock
2026
HKD15.6b 8.21%
Unlock
2027
HKD17.5b 12.14%
Unlock
2028
HKD25.2b 43.77%
Unlock
2029
HKD28.6b 13.51%
Unlock

18 Analysts have issued an Hansoh Pharmaceutical Group Company EBITDA forecast 2025. The average Hansoh Pharmaceutical Group Company EBITDA estimate is

HKD5.3b
Unlock
. This is
12.16% higher
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
HKD6.6b 40.74%
Unlock
, the lowest is
HKD3.7b 21.69%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2024 HKD4.7b 38.82%
2025
HKD5.3b 12.14%
Unlock
2026
HKD5.5b 4.78%
Unlock
2027
HKD6.4b 15.22%
Unlock

EBITDA Margin

2024 35.51% 16.59%
2025
36.69% 3.33%
Unlock
2026
35.53% 3.16%
Unlock
2027
36.51% 2.76%
Unlock

10 Hansoh Pharmaceutical Group Company Analysts have issued a net profit forecast 2025. The average Hansoh Pharmaceutical Group Company net profit estimate is

HKD4.6b
Unlock
. This is
2.15% lower
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
HKD5.1b 8.44%
Unlock
, the lowest is
HKD4.3b 9.85%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2024 HKD4.7b 31.15%
2025
HKD4.6b 2.15%
Unlock
2026
HKD4.9b 5.23%
Unlock
2027
HKD5.9b 19.68%
Unlock
2028
HKD9.6b 64.34%
Unlock
2029
HKD10.9b 13.44%
Unlock

Net Margin

2024 35.72% 10.15%
2025
32.21% 9.83%
Unlock
2026
31.32% 2.76%
Unlock
2027
33.43% 6.74%
Unlock
2028
38.21% 14.30%
Unlock
2029
38.19% 0.05%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029

Create a premium account to unlock analyst estimates. Learn more

Dec '24 2025
Estimates
Earnings Per Share HKD 0.80 0.78
31.15% 2.50%
P/E 30.28
EV/Sales 8.03

10 Analysts have issued a Hansoh Pharmaceutical Group Company forecast for earnings per share. The average Hansoh Pharmaceutical Group Company EPS is

HKD0.78
Unlock
. This is
2.50% lower
Unlock
than earnings per share in the financial year 2024. The highest EPS forecast is
HKD0.87 8.75%
Unlock
, the lowest is
HKD0.72 10.00%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2024 HKD0.80 31.15%
2025
HKD0.78 2.50%
Unlock
2026
HKD0.82 5.13%
Unlock
2027
HKD0.99 20.73%
Unlock
2028
HKD1.62 63.64%
Unlock
2029
HKD1.84 13.58%
Unlock

P/E ratio

Current 29.63 16.42%
2025
30.28 2.19%
Unlock
2026
28.77 4.99%
Unlock
2027
24.04 16.44%
Unlock
2028
14.63 39.14%
Unlock
2029
12.90 11.83%
Unlock

Based on analysts' sales estimates for 2025, the Hansoh Pharmaceutical Group Company stock is valued at an EV/Sales of

and an P/S ratio of .

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 8.72 40.42%
2025
8.03 7.88%
Unlock
2026
7.42 7.59%
Unlock
2027
6.62 10.82%
Unlock
2028
4.60 30.45%
Unlock
2029
4.06 11.90%
Unlock

P/S ratio

Current 10.58 28.50%
2025
9.75 7.85%
Unlock
2026
9.01 7.59%
Unlock
2027
8.03 10.82%
Unlock
2028
5.59 30.45%
Unlock
2029
4.92 11.90%
Unlock

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today